Financial reports
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
30 Oct 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
10-Q
2023 Q1
Quarterly report
2 May 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
10-K
2021 FY
Annual report
28 Feb 22
Current reports
8-K
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
27 Mar 24
8-K
MIMEDX Announces Appointment of Two New Independent Directors
4 Mar 24
8-K
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
28 Feb 24
8-K
MIMEDX Announces Improved Capital Structure with New Senior
22 Jan 24
8-K
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
28 Dec 23
8-K
MIMEDX to Participate in Upcoming Investor Conferences
13 Nov 23
8-K
MIMEDX Announces Third Quarter 2023 Operating and Financial Results
30 Oct 23
8-K
Departure of Directors or Certain Officers
5 Sep 23
8-K
MIMEDX to Present at Upcoming Investor Conferences
5 Sep 23
8-K
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
1 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
25 Jul 23
S-8
Registration of securities for employees
25 Jul 23
S-8
Registration of securities for employees
9 Mar 23
S-8
Registration of securities for employees
17 Jun 22
S-3
Shelf registration
27 Aug 21
S-8
Registration of securities for employees
17 Dec 20
8-A12B
Registration of securities on exchange
2 Nov 20
25-NSE
Exchange delisting
26 Feb 19
8-A12G
Registration of securities
7 Nov 18
S-8
Registration of securities for employees
7 Jun 16
Proxies
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
DEF 14A
Definitive proxy
15 May 23
PRE 14A
Preliminary proxy
4 May 23
DEFA14A
Additional proxy soliciting materials
3 Jun 22
DEFA14A
Additional proxy soliciting materials
2 Jun 22
DEFA14A
Additional proxy soliciting materials
31 May 22
DEFA14A
Additional proxy soliciting materials
25 May 22
DEFA14A
Additional proxy soliciting materials
20 May 22
DEFA14A
Additional proxy soliciting materials
18 May 22
Other
EFFECT
Notice of effectiveness
8 Sep 21
CORRESP
Correspondence with SEC
2 Sep 21
UPLOAD
Letter from SEC
2 Sep 21
CORRESP
Correspondence with SEC
26 Apr 21
UPLOAD
Letter from SEC
26 Apr 21
UPLOAD
Letter from SEC
26 Apr 21
CERT
Certification of approval for exchange listing
3 Nov 20
UPLOAD
Letter from SEC
13 Jun 19
CORRESP
Correspondence with SEC
3 Jun 19
UPLOAD
Letter from SEC
31 May 19
Ownership
4
William Frank IV Hulse
24 Apr 24
4
William Frank IV Hulse
10 Apr 24
3
DOROTHY E PUHY
18 Mar 24
3
Tiffany Olson
18 Mar 24
4
William Frank IV Hulse
15 Mar 24
4
William Frank IV Hulse
5 Mar 24
4
Ricci S Whitlow
5 Mar 24
4
RICE DOUG
5 Mar 24
4
Ricci S Whitlow
21 Feb 24
144
Notice of proposed sale of securities
20 Feb 24